Ketamine for Depression, 3: Does Chirality Matter?: (Clinical and Practical Psychopharmacology)
The DOI matches its Crossref record.
Abstract
Ketamine is a racemic mixture of the enantiomers R-ketamine and S-ketamine (esketamine). S-ketamine has greater analgesic and anesthetic effects than R-ketamine and is less likely to cause psychotomimetic and other adverse effects. There is therefore an emerging interest favoring the use of S-ketamine over racemic ketamine when the drug is used for analgesia or anesthesia. This article examines preclinical and clinical literature on the antidepressant properties of S-ketamine. Animal data suggest potential advantages for R-ketamine over S-ketamine. Case reports, case series, and some small randomized controlled trials suggest that single or repeated intravenous infusions (0.2-0.4 mg/kg) or intranasal administrations (28-84 mg) of S-ketamine have antidepressant action in patients with medication-refractory depression and that the observed benefits are similar in magnitude to the antidepressant benefits reported with racemic ketamine. However, there are no direct comparisons between S-ketamine and either R-ketamine or racemic ketamine in depressed patients; therefore, it is not possible to make an informed choice when considering the enantiomers and the racemate for the indication of depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The S-enantiomer of ketamine (esketamine) is a more potent antagonist than R-ketamine at the phencyclidine site on the glutamate NMDA receptor,27–31 and has stronger analgesic potency than either R-ketamine or racemic ketamine.32”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [29]
Citations
Cites
Still being checked.
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Marcantoni, W. S., Akoumba, B. S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., & Beauchamp, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.007 · Cited by 246
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Correia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
De Berardis, D., Fornaro, M., Valchera, A., Cavuto, M., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102888 · Cited by 174
Esketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
“may reside primarily in one enantiomer, and the two enantiomers may influence each other’s pharmacokinetics [28,29].”
BackgroundThe Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Ma, J., Wang, F., Wang, J., Wang, P., Dou, X., Yao, S., & Lin, Y. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s406568 · Cited by 80
Gärtner, M., Aust, S., Bajbouj, M., Fan, Y., Wingenfeld, K., Otte, C., Heuser-Collier, I., Böker, H., Hättenschwiler, J., Seifritz, E., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.008 · Cited by 66
Strong, C. E., & Kabbaj, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.09.001 · Cited by 60
Correia-Melo, F. S., Leal, G. C., Carvalho, M. S., Jesus-Nunes, A. P., Ferreira, C. B. N., Vieira, F., Magnavita, G., Vale, L. A. S., Mello, R. P., Nakahira, C., et al. (2018) · Medicine · doi:10.1097/md.0000000000012414 · Cited by 61
Cheng, X., Wang, H., Diao, M., & Jiao, H. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.04.028 · Cited by 59
Sattar, Y., Wilson, J., Khan, A., Adnan, M., Larios, D. A., Shrestha, S., Rahman, Q., Mansuri, Z., Hassan, A., Patel, N. B., et al. (2018) · Cureus · doi:10.7759/cureus.2652 · Cited by 64
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Berardis, D. D., Tomasetti, C., Pompili, M., Serafini, G., Vellante, F., Fornaro, M., Valchera, A., Perna, G., Volpe, U., Martinotti, G., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200131100316 · Cited by 47
Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312102444 · Cited by 44
The evolutionary old forebrain as site of action to develop new psychotropic drugs
LOONEN, A. J. M., & Ivanova, S. А. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798617 · Cited by 41
Lucchese, A. C., Sarin, L. M., Magalhães, E. T. P., Sant, L. C. D., Puertas, C. B., Tuena, M. A., Nakahira, C., Fava, V. A. R., Delfino, R. S., Surjan, J. C., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120978398 · Cited by 39
Souza‐Marques, B., Santos‐Lima, C., Araújo-de-Freitas, L., Vieira, F., Jesus‐Nunes, A. P., Quarantini, L. C., & Sampaio, A. S. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000312 · Cited by 43
Spies, M., James, G. M., Berroterán-Infante, N., Ibeschitz, H., Kranz, G. S., Unterholzner, J., Godbersen, M., Gryglewski, G., Hienert, M., Jungwirth, J., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx085 · Cited by 34
“, 2015) properties are a current topic of intense research (Andrade, 2017).”
BackgroundKetamine effects on anxiety and fear-related behaviors: Current literature evidence and new findings
Silote, G. P., de Oliveira, S. F. S., Ribeiro, D. E., Machado, M. S., Andreatini, R., Joca, S. R. L., & Beijamini, V. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109878 · Cited by 35
Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence
Andrade, C. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19f12820 · Cited by 49
Self-citationStippl, A., Scheidegger, M., Aust, S., Herrera, A., Bajbouj, M., Gärtner, M., & Grimm, S. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.028 · Cited by 29
Sachdeva, B., Sachdeva, P., Ghosh, S., Ahmad, F., & Sinha, J. K. (2023) · Ibrain · doi:10.1002/ibra.12094 · Cited by 34
Citrome, L., DiBernardo, A., & Singh, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 26
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors
Gomes, I., Gupta, A., Margolis, E. B., Fricker, L. D., & Devi, L. A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000947 · Cited by 31
Abdoulaye, I. A., Wu, S.-S., Chibaatar, E., Yu, D., Le, K., Cao, X., & Guo, Y. (2021) · Neural Plasticity · doi:10.1155/2021/6635084 · Cited by 26
Włodarczyk, A., & Cubała, W. J. (2020) · Medicina · doi:10.3390/medicina56020067 · Cited by 25
Histoire de la kétamine : une molécule ancienne qui a toujours la cote
Daré, B. L., Pelletier, R., Morel, I., & Gicquel, T. (2021) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2021.04.005 · Cited by 33
Role of Ketamine in the Treatment of Psychiatric Disorders
Derakhshanian, S., Zhou, M., Rath, A., Barlow, R., Bertrand, S. C., DeGraw, C., Lee, C., Hasoon, J. J., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.25091 · Cited by 27
Hirota, K., & Lambert, D. G. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.08.020 · Cited by 20
Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 25
Chen, H., Zhi, J., Wang, L., Jin, Z., Xu, J., Xing, F., Wen, C., Wang, Q., Chen, C., Li, W., et al. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s470891 · Cited by 22
Craving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
Włodarczyk, A., Cubała, W. J., Szarmach, J., Małyszko, A., & Wiglusz, M. S. (2019) · PubMed · Cited by 19
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Xiao, C., Zhou, J. L., Li, A., Zhang, L., Zhu, X., Zhou, J., Hu, Y., Zheng, Y., Liu, J., Deng, Q., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28817 · Cited by 14
Włodarczyk, A., Słupski, J., Szarmach, J., & Cubała, W. J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104016 · Cited by 14
Zheng, W., Zhou, Y., Wang, C., Lan, X., Zhang, B., Zhou, S., Yan, S., Yang, M., Nie, S., & Ning, Y. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211014320 · Cited by 11
Liang, Z., Wang, D., Jin, X., Fan, L., Wen, X., Wei, C., & Li, X. (2023) · Journal of Neural Engineering · doi:10.1088/1741-2552/acc2e8 · Cited by 10
Souza‐Marques, B., Telles, M., Leal, G. C.-G., Faria-Guimarães, D., Correia‐Melo, F. S., Jesus‐Nunes, A. P., Vieira, F., Souza, L. S., Lins-Silva, D. H., Mello, R. P., et al. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001571 · Cited by 13
Yadav, A., Dogra, S., Boda, A. K., Kumari, P., Kumar, A., Dash, M. K., & Yadav, P. N. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00175 · Cited by 9
Sakopoulos, S., & Todman, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146673 · Cited by 12
A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry
Andrade, C., & Rao, T. S. (2017) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_345_17 · Cited by 13
Self-citationOyetunji, A. O., Huelga, C., Bunte, K., Tao, R., & Bellman, V. (2023) · AIMS Public Health · doi:10.3934/publichealth.2023043 · Cited by 13
Chiral Resolution of dl -Leucine by the Diastereomeric Salt/Cocrystal Method
Shi, L., Wang, N., Huang, X., Wang, T., Hao, H., & Zhou, L. (2025) · Crystal Growth & Design · doi:10.1021/acs.cgd.5c00809 · Cited by 8
Antidepressants and the endogenous opioid system
Fricker, L. D., Osman, A., Gupta, A., Gomes, I., & Devi, L. A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117392 · Cited by 12
Cigognini, M. A., Guirado, A. G., van de Meene, D., Schneider, M. A., Salomon, M. S., de Alexandria, V. S., Adriano, J. P., Thaler, A. M., Fernandes, F. D. S., Carneiro, A. M., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.830301 · Cited by 9
Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives
Courault, P., Demarquay, G., Zimmer, L., & Lancelot, S. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12636 · Cited by 9
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Banov, M. D., Landrum, R. E., Moore, M. B., & Szabo, S. T. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001456 · Cited by 6
Nabati, M., Bodaghi-Namileh, V., & Sarshar, S. (2019) · Progress in Chemical and Biochemical Research · doi:10.33945/sami/pcbr.2019.2.4 · Cited by 12
Gutiérrez, G., Rosenblat, J. D., Hawken, E. R., Swainson, J., & Vázquez, G. H. (2022) · JMIR Research Protocols · doi:10.2196/34711 · Cited by 7
Vázquez, G. H., Gutiérrez, G., Rosenblat, J. D., Schaffer, A., Swainson, J., Ganapathy, K., Ravindran, N., Lam, R. W. M., Do, A., Giacobbe, P., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060967 · Cited by 9
Li, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01920-x · Cited by 5
“One study comparing the therapeutic effects of ketamine and esketamine for depression showed that the antidepressant effects of ketamine and escitalopram appear to be similar [ 59, 60].”
Research trends and hotspots of ketamine from 2014 to 2023: a bibliometric analysis
Wang, Y., Chang, S., & Chen, D. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1407301 · Cited by 9
Faruqui, Z., & Kim, C. (2022) · Case Reports in Psychiatry · doi:10.1155/2022/8992697 · Cited by 5
Case series of intravenous ketamine infusion in patients with suicidal thought
Sharma, P., Dubey, A., Gajbhiye, D., Sharma, A., & Kant, A. (2023) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_19_23 · Cited by 4
Dexoxadrol and its bioisosteres: structure, synthesis, and pharmacological activity
Novakov, I. A., Шейкин, Д. С., Навроцкий, М. Б., Mkrtchyan, A. S., Brunilina, L. L., & Balakin, K. V. (2020) · Russian Chemical Bulletin · doi:10.1007/s11172-020-2946-9 · Cited by 4
Han, J., Zhang, X., Xia, L., Liao, O., & Li, Q. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-022-00243-z · Cited by 4
Barbara, A. M., Xie, W., Mahood, Q., & Hamson, A. (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.817 · Cited by 5
Gender Differences in Adverse Events of Ketamine Drugs: A Real‐World Study Based on FAERS
Zhang, J., Guo, Q., Zhang, R., Wei, M., & Nie, Z. (2024) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2024/4898082 · Cited by 4
Xu, R., Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., & Luca, S. M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-3207199/v1 · Cited by 4
A Systematic Review of Intra-Articular Ketamine for Postoperative Analgesia
Covington, S. M., D'Souza, R. S., Erwin, P. J., & Qu, W. (2020) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001483 · Cited by 3
Intranasal esketamine for depression: Not so special K
Rosenman, S. J. (2022) · Australasian Psychiatry · doi:10.1177/10398562221093870 · Cited by 2
Ketamine and Electroconvulsive Therapy for Depression
Andrade, C. (2018) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000524 · Cited by 2
Self-citationKetamine for Depression in Serious Illness: Evidence, Safety, and Practical Approaches
Noufi, P. E., Borris, J. B., Chammas, D., McDermott, C. L., Ufere, N. N., Webb, J. A., & Shalev, D. (2026) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2026.04.604 · Cited by 1
Role of ketamine in treatment-resistant depression
Dmochowska, J., Ciechański, M., Cieszkowska, J., Czerwik, J., Czubala, M., Felisiak, P., Gąska, W., Kanon, K., & Witkowska, E. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.58492 · Cited by 2
Ketamines for Treatment Resistant Depression in Patients with Chronic Pain and Opioid Use
Hart, M., & Cernovsky, Z. Z. (2019) · Archives of Psychiatry and Behavioral Sciences · doi:10.22259/2638-5201.0202008 · Cited by 1
Cohen, J., Reichelt, A. C., Zamyadi, R., Roberts, G., Hardy, S., Fernandes, B., Rhind, S. G., Lewis, E. C., Bhat, V., Palner, M., et al. (2025) · medRxiv · doi:10.1101/2025.02.25.25322463 · Cited by 4
Intranasal esketamine in treatment-resistant depression: a profile of its use
Scott, L. J. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00675-z · Cited by 1
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.99765
Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder
Tran, K. T., & Mahood, Q. (2022) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2022.308
Perspective Chapter: Ketamine, Depression, and Gender Bias
Alshammari, T. K., Alseraye, S., Al-Rasheed, N. M., Dayel, A. F. B., Alonazi, A. S., Sabhan, J. F. A., & Alshammari, M. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103656
Introductory Chapter: Is Ketamine the New Panacea of the 21 st Century?
Sáiz‐Sapena, N., & Granell, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104966
Cigognini, M. A. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-10052023-120550
ANYIOM, O. P., JULIUS, A., Okolo, R. U., Donatus, A. A., GBENGA, E., UGBAKA, A. C., & EMMANUEL, O. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024.v17i3.49464 · Cited by 1
Yang, X., Gao, T. Y., Wang, S. Y., Hu, L., Huang, F., Cui, W., & Zhang, L. (2026) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2026.112246 · Cited by 1
Metadata
- Authors
- Andrade, C.
- Affiliations
- National Institute of Mental Health and Neurosciences (IN)
- Corresponding author
- Andrade, Chittaranjan
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2017-06-28
- Volume
- 78
- Issue
- 06
- Pages
- e674-e677
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2730146128
- Cited by
- 78
- References
- 0
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 12 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 9 · 2019: 9 · 2018: 9 · 2017: 2
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, (R)-ketamine, chirality, enantiomers, antidepressant effects, treatment-resistant depression, intranasal administration, intravenous infusion
- MeSH terms
- Animals, Antidepressive Agents, Humans, Ketamine, Stereoisomerism, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.